Janux Therapeutics Stock Today
| JANX Stock | USD 48.52 6.46 11.75% |
Performance6 of 100
| Odds Of DistressLess than 25
|
Janux Therapeutics is trading at 48.52 as of the 5th of June 2024; that is -11.75 percent decrease since the beginning of the trading day. The stock's open price was 54.98. Janux Therapeutics has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Janux Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of March 2024 and ending today, the 5th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of June 2021 | Category Healthcare | Classification Health Care |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. The company has 51.85 M outstanding shares of which 2.88 M shares are currently shorted by private and institutional investors with about 3.31 trading days to cover. More on Janux Therapeutics
Moving against Janux Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Janux Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | David Campbell | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janux Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Janux Therapeutics' financial leverage. It provides some insight into what part of Janux Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janux Therapeutics (JANX) is traded on NASDAQ Exchange in USA. It is located in 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130 and employs 68 people. Janux Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.7 B. Janux Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 51.85 M outstanding shares of which 2.88 M shares are currently shorted by private and institutional investors with about 3.31 trading days to cover.
Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15.
Check Janux Therapeutics Probability Of Bankruptcy
Ownership AllocationJanux Therapeutics has a total of 51.85 Million outstanding shares. The majority of Janux Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Janux Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Janux Therapeutics. Please pay attention to any change in the institutional holdings of Janux Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost four million six hundred sixty-six thousand five hundred sixty-three invesors are currently shorting Janux Therapeutics expressing very little confidence in its future performance.
Check Janux Ownership Details
Janux Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-03-31 | 467.5 K | |
| State Street Corporation | 2024-03-31 | 399.5 K | |
| Avidity Partners Management Lp | 2024-03-31 | 384.2 K | |
| Samlyn Capital, Llc | 2024-03-31 | 296.4 K | |
| Two Sigma Investments Llc | 2024-03-31 | 224.7 K | |
| Northern Trust Corp | 2024-03-31 | 202 K | |
| Alyeska Investment Group, L.p. | 2024-03-31 | 193 K | |
| Driehaus Capital Management Llc | 2024-03-31 | 191.1 K | |
| Samsara Biocapital, Llc | 2024-03-31 | 180.2 K | |
| Ra Capital Management, Llc | 2024-03-31 | 9.2 M | |
| Fmr Inc | 2024-03-31 | 7.7 M |
Janux Therapeutics Historical Income Statement
Janux Stock Against Markets
Janux Therapeutics Corporate Management
| Brenda Vreeswyk | Head Resources | Profile | |
| Byron JD | Chief Officer | Profile | |
| Wayne MD | Chief Officer | Profile | |
| Tommy Diraimondo | Director Research | Profile | |
| Charles Winter | Manufacturing Chemistry | Profile | |
| CFA CPA | Acting Officer | Profile |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.